NewsBite

Pharmaceuticals

March

StrongRoom AI goes into administration two weeks after $70m valuation

The future of the software start-up, which will be put up for sale, has been in doubt since EVP, a venture capital investor, raised doubts about its finances.

Dr. David Fajgenbaum, left, with Joseph Coates, after finding a lifesaving drug regimen for Coates that an artificial intelligence model suggested

Doctors told him he was going to die. Then AI saved his life

In labs around the world, scientists are using AI to search among existing medicines for treatments that work for rare diseases.

Trump could target our healthcare system next. We don’t need to panic

If there are retaliatory tariffs because of standing up for our PBS jewel, so be it. That would be unfortunate and unfair, but Australia can weather it.

Australian beef exports to China reached new highs in October, topping 30,000 tonnes for the month.

Billions in beef exports at stake from Trump’s tariff war

US cattle ranchers and sheep graziers have recently restated their long-standing complaints against the Australian industry.

Uni side hustle grows to nearly $70m valuation

Three friends have turned their university side hustle into a software business after landing new venture capital investors.

Advertisement

February

John Boland, prostate cancer drug patient.

Big pharma sues GenesisCare over Labor-endorsed copycat cancer drug

Swiss pharma giant Novartis is taking legal action against the Australian cancer care provider as a dispute over how to fund and regulate nuclear medicines escalates.

Sales of Mayne Pharma’s birth control pills and other women’s health products have underpinned the company’s improved performance this year.

US pharma giant Cosette makes $672m bid for Mayne Pharma

US pharma giant Cosette has offered $7.40 a share for Mayne Pharmaceuticals, a premium to recent trading but a fraction of the $42 it was trading at in 2016.

January

Chemist Warehouse founders Jack Gance, Mario Verrocchi and Sam Gance.

New Chemist Warehouse riches revealed: 53 investors worth over $50m

Exclusive analysis of the share registry has unveiled for the first time just how many millionaires its merger with Sigma will mint.

A flower from Madagascar called a periwinkle contains compounds scientists have used to treat cancer.

Drugs from nature help millions. But there’s a catch

Big pharma and others that have made a buck from genetic resources have been asked to funnel some profit back to communities where the organisms come from.

Eli Lilly’s headquarters in Indiana. The emergence of Mounjaro as an effective treatment for obesity has been a boon to the company’s share price.

Global pharma giants push for weight-loss drugs to be added to PBS

Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the popular obesity treatment.

November 2024

The ACCC delayed its decision on Sigma Healthcare’s $8.8 billion merger with Chemist Warehouse several times.

‘Critical milestone’: Chemist Warehouse, Sigma merger clears ACCC hurdle

After several delays, the regulator found the tie-up will not substantially hurt competition, paving the way for the creation of a $28.9 billion sharemarket giant.

October 2024

Chemist Warehouse is a dominant pharmacy chain, and has proposed merging with Sigma Healthcare.

Pharmacy lobby says Chemist Warehouse concessions are ‘tokenistic’

The influential industry group is urging the competition regulator to reject an $8.8 billion merger with Sigma Healthcare. A decision is due early next month.

John Cullity, CEO Ebos Group, says the Sigma-Chemist Warehouse merger will weaken the independent pharmacies.

Ebos CEO takes swing at $8.8b Chemist Warehouse-Sigma deal

The chief executive of the pharmacy group behind TerryWhite Chemmart says the merger, being assessed by the competition regulator, would harm the health network.

Jack Gance, chairman and co-founder of Chemist Warehouse.

Chemist Warehouse goes to war with card fees – using QR codes

The pharmacy and retailing giant pays $15 million in transaction costs every year. Now it has signed on to a new NAB-backed system that circumvents them.

Person with pill.

People are taking a pill to extend their lives. Will it work?

Rapamycin is typically prescribed as an immunosuppressive, but off-label users believe it can do much more.

Advertisement

September 2024

Models walk the runway as part of  Paris Fashion Week.

Everyone’s on Ozempic, so why won’t anyone ‘admit’ it?

The fashion world is embracing weight-loss drugs – but very discreetly.

Adam Steensberg: “Obesity is the biggest healthcare challenge of our time.”

The doctor-turned-CEO aiming to beat Ozempic

Adam Steensberg leads Zealand Pharma, a Danish drug maker whose stock has risen by more than 800 per cent since he took over in 2022.

BlackRock will look to acquire existing research laboratories.

BlackRock seeds $1.5b laboratory real estate fund

BlackRock is partnering with local private equity firm Wentworth Capital on a “pure play” laboratory fund that has already secured a number of seed assets

Vikesh Ramsunder, CEO of Sigma Healthcare, expects the ACCC to make a call on its merger with Chemist Warehouse on October 24.

ACCC call on Sigma, Chemist Warehouse $8.8b tie-up due in four weeks

Merger plans are tracking in line with expectations, with the competition watchdog to make a final decision on October 24 after a previous delay.

Telix CEO Christian Behrenbruch has upgraded 2024 revenue forecasts.

Telix on $1b spending spree to build US radiopharmacy network

The biotech is investing heavily in global networks that will enable it to control the supply and distribution of nuclear medicines used to treat cancer.

Original URL: https://www.afr.com/topic/pharmaceuticals-hnn